Novanta Inc SEC Filings

Novanta Inc. amended its main credit agreement to add $200.0 million in delayed draw term loan commitments. This new facility can be drawn at the company’s option for up to six months after May 15, 2026, giving additional funding flexibility.

The Delayed Draw Term Loans will mature on June 27, 2030 and bear interest at either the Base Rate plus 0.00%-0.75% or SOFR/SONIA/EURIBOR plus 1.00%-1.75%, depending on Novanta’s consolidated leverage ratio. The loans amortize quarterly starting with the fiscal quarter ending September 25, 2026, initially at 0.625% of outstanding U.S. dollar term loans, increasing to at least 1.25% from late June 2027. Novanta will also pay a commitment fee on undrawn amounts, and its incremental term loan and revolver capacity are reset from the amendment date.

NOVANTA INC Chief Executive Officer Matthijs Glastra reported selling common stock in a pre-planned transaction. On May 12, 2026, he completed open-market sales totaling 7,500 shares at prices around $150–$151.34 per share under a pre-established Rule 10b5-1 trading plan.

Following these sales, he directly held 42,761 shares of Novanta common stock and indirectly held 54,382 shares through the Matthijs Glastra 2021 Irrevocable Trust. One sale at a weighted-average price of $151.34 was executed in multiple trades between $151.06 and $151.51.

Novanta, Inc. submitted Rule 144 notices reporting proposed resale of common stock by an affiliate and recent open-market sales. The filing lists a proposed sale quantity of 7,500 shares tied to Merrill Private Wealth Management and shows multiple previously reported sales by Matthijs Glastra totaling 26,000 shares across four transactions dated 02/10/2026, 03/02/2026, 04/17/2026, and 05/05/2026.

The excerpt also itemizes Restricted Stock Units granted on 02/25/2020 (3,618 RSUs), 02/24/2020 (1,744 RSUs), 03/03/2017 (1,870 RSUs) and 02/26/2017 (268 RSUs). Dollar proceeds are shown for each recent sale in the table (for example, $1,087,500 for the 02/10/2026 sale).

Novanta Inc. reported solid Q1 2026 revenue growth while earnings were roughly flat. Revenue rose to $257.7M from $233.4M, driven by both Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies generated $131.2M and Medical Solutions $126.5M of revenue.

Net income was stable at $21.1M versus $21.2M a year earlier, with diluted EPS slipping to $0.51 from $0.59 as the share count increased. Operating income declined to $27.5M from $32.4M as selling, general and administrative expenses and restructuring and acquisition costs increased.

Operating cash flow strengthened to $51.6M from $31.7M, supporting a cash balance of $388.8M and total debt of $241.4M. The company continued buybacks, repurchasing 159 thousand shares for $18.6M, and ended the quarter with 35.6M common shares outstanding.

Novanta Inc. reported solid first quarter 2026 results with growth in sales, earnings on a non-GAAP basis, and strong cash generation. GAAP revenue rose 10.4% to $257.7 million, helped by acquisitions and favorable currency, while organic revenue increased 3.1%. GAAP net income was stable at $21.1 million, but diluted EPS declined to $0.51 from $0.59 as operating expenses grew.

Profitability looked stronger on a non-GAAP basis. Adjusted EBITDA increased 14.2% to $57.1 million, with margin at 22.1%, and Adjusted diluted EPS rose to $0.81 from $0.74. Operating cash flow jumped to $51.6 million, driving Free Cash Flow of $47.8 million and leaving the company in a net cash position of about $139 million. Management highlighted 37% year-over-year bookings growth and guided Q2 2026 GAAP revenue to $259–$264 million, with full-year 2026 revenue expected between $1.04 billion and $1.055 billion, and higher Adjusted EBITDA and EPS, reflecting confidence in demand across medical and advanced industrial end markets.

Novanta Inc. Chief Executive Officer Matthijs Glastra sold 6,500 shares of common stock in open-market transactions on May 5, 2026, under a pre-established Rule 10b5-1 trading plan. The trades were executed at weighted-average prices within disclosed ranges, and Glastra also reports indirect ownership of 54,382 shares through a 2021 irrevocable trust.

Novanta, Inc. (NOVT) related party filed a Form 144 to sell common stock. The filing lists 6,500 shares with an aggregate value of $845,000 and references 35,683,769 shares outstanding as of 05/05/2026. The notice names Merrill Private Wealth Management and shows multiple recent sales by Matthijs Glastra totaling repeated tranches of 6,500 and 7,500 shares on dates in early 2026.

Novanta Inc reports a Schedule 13G filing showing Vanguard Capital Management beneficially owns 1,886,765 shares (5.27%). The filing states Vanguard has sole dispositive power over 1,886,765 shares and sole voting power over 273,550 shares. The filing is signed by Ashley Grim on 04/30/2026.

This Schedule 13G discloses ownership on behalf of Vanguard-managed accounts, noting holdings include securities held by Vanguard funds and certain affiliates. The filing lists corporate addresses for Novanta and Vanguard and affirms no single other person holds more than 5% of the class.

Vanguard Portfolio Management reported beneficial ownership of 2,508,270 shares of Novanta Inc Common Stock, representing 7.01% of the class as of 03/31/2026. The filing shows sole voting power for 31,389 shares and sole dispositive power for 2,508,270 shares. The disclosure was signed on 04/29/2026 by Ashley Grim.